From: Residual macrovascular risk in 2013: what have we learned?
Effects on atherogenic dyslipidaemia* | Other effects | Outstanding issues | |||
---|---|---|---|---|---|
Treatment group/example | Dose | Triglycerides | HDL-C | ||
[reference]; duration | |||||
SPPARMs: K-877 [81] | 100 μg BID | ↓70% | ↑18% | Improved safety profile (CV, renal and hepatic biomarkers) versus fenofibrate | ● Outcomes data, long-term safety |
12 weeks | |||||
Dual PPAR agonists | |||||
GFT505 (dual PPARα/δ) [84] | 80 mg OD | ↓17-25% | ↑8-9% | Improved safety profile (hepatic biomarkers) | ● Lower efficacy than current PPARα agonists |
4 weeks | ● Outcomes data, long-term safety | ||||
CETP inhibitors | |||||
Anacetrapib1[85] | 100 mg OD | ↓7% | ↑138% | Decreases in LDL-C (~40%), Lp(a) and apoB | ● Outcomes data, long-term safety |
24 weeks | |||||
Evacetrapib1[86] | 100 mg OD | NA | ↑~80% | Decreases in LDL-C (36%); data on other lipid effects NA | ● Outcomes data, long-term safety |
12 weeks | |||||
PCSK9 targeted therapy | |||||
Alirocumab1[87] | 150 mg every 2 weeks | ↓19% | ↑6% | Decreases in LDL-C (>60%); also Lp(a) and apoB | ● Outcomes data, long-term safety |
12 weeks | |||||
AMG 1451,2[88] | 140 mg every 2 weeks | ↓34% | ↑8% | Decreases in LDL-C (>60%), Lp(a) and apoB | ● Outcomes data, long-term safety |
12 weeks |